Corteva (NYSE:CTVA – Get Free Report) will post its quarterly earnings results after the market closes on Wednesday, November 6th. Analysts expect Corteva to post earnings of ($0.29) per share for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.
Corteva Stock Performance
Shares of NYSE CTVA opened at $61.21 on Tuesday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.17 and a current ratio of 1.72. The firm has a market cap of $42.37 billion, a price-to-earnings ratio of 47.08, a P/E/G ratio of 1.75 and a beta of 0.77. The business’s 50-day simple moving average is $57.90 and its 200-day simple moving average is $55.45. Corteva has a 52 week low of $43.22 and a 52 week high of $62.38.
Corteva Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Monday, December 16th. Investors of record on Monday, December 2nd will be paid a dividend of $0.17 per share. The ex-dividend date of this dividend is Monday, December 2nd. This represents a $0.68 annualized dividend and a yield of 1.11%. Corteva’s payout ratio is 52.31%.
Wall Street Analysts Forecast Growth
View Our Latest Analysis on Corteva
Corteva Company Profile
Corteva, Inc operates in the agriculture business. It operates through two segments, Seed and Crop Protection. The Seed segment develops and supplies advanced germplasm and traits that produce optimum yield for farms. It offers trait technologies that enhance resistance to weather, disease, insects, and herbicides used to control weeds, as well as food and nutritional characteristics.
Featured Articles
- Five stocks we like better than Corteva
- CD Calculator: Certificate of Deposit Calculator
- Intel: Is Now the Time to Be Brave?
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for Corteva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corteva and related companies with MarketBeat.com's FREE daily email newsletter.